Celon Pharma Sa · GPW:CLN
Celon Pharma Sa — Investor Day (October 2022)
7 slides from Celon Pharma Sa's investor day presentation, October 2022
Slide 1: Immunology
Immunology Piotr Pankiewicz Clinical Development Leader Celon Pharma Investor Day 2022
Slide 2: Immunology projects
Immunology projects CLINICAL DEVELOPMENT INDICATION MOLECULAR TARGET RESEARCH PRE-CLINICAL DEVELOPMENT PHASE | PHASE Il Autoimmune 7 JAK/ROCK Inhibitor : > diseases * cae 5g « Autoimmune Bispecific scaffolds diseases ** targeting immune system
Slide 3: CPL'116: Dual inhibitor with broad therapeutic properties
CPL’116 Dual inhibitor with a broad therapeutic properties ROCK KINASE JAK KINASE INHIBITION INHIBITION Anti-fibrotic component Anti-inflammatory component
Slide 4: CPL'116 – Clinical Development Overview
CPL’116 – Clinical Development Overview PHASE 1 PHASE 2 01JAK2020 03JAK2021 65 healthy volunteers 100 RA patients Safety, PK, PD 12 weeks vs placebo Single and multiple dose Efficacy, Safety, PK/PD Q4 2020 – Q3 2021 Q1 2022 – Q2 2023 ▪ No serious adverse events after single or multiple administratio
Slide 5: CPL'116 - Phase 2 | RA
CPL’116 - Phase 2 | RA A 12-week, phase II, multicentre, randomised, double blind, efficacy and safety study comparing CPL409116 to placebo, in combination with methotrexate in participants with active rheumatoid arthritis who have an inadequate response to methotrexate. POLAND RA approval Q1 2022 P
Slide 6: CPL'116 – Clinical Development Plans
CPL’116 – Clinical Development Plans PHASE 1 PHASE 2 PHASE 2 01JAK2020 03JAK2021 65 healthy volunteers 100 RA patients Idiopathic Pulmonary Fibrosis Safety, PK, PD 12 weeks vs placebo Single and multiple dose Efficiency, Safety, PK/PD Q4 2020 – Q3 2021 Q1 2022 – Q2 2023 Q1 2023 – 2024 Q2 2023 – 2024
Slide 7: Piotr Pankiewicz, Clinical Development Leader
Piotr Pankiewicz Clinical Development Leader piotr.pankiewicz@celonpharma.com Celon Pharma Investor Day 2022